Pharmacy Department, Kaiser Permanente Colorado, 16601 E. Centretech Parkway, Aurora, CO 80011, USA.
J Clin Lipidol. 2010 May-Jun;4(3):173-80. doi: 10.1016/j.jacl.2010.03.002. Epub 2010 Mar 16.
The National Cholesterol Education Program Guidelines offer an optional low-density lipoprotein cholesterol (LDL-C) goal of less than 70 mg/dL for very high-risk patients with coronary artery disease (CAD). This study evaluated the extent to which this recommendation can be attained by the use of currently available lipid-lowering therapies.
A retrospective, cross-sectional study of patients in the Kaiser Permanente Colorado healthcare system 18 years of age or older with CAD and a predetermined LDL-C goal less than 70 mg/dL. The LDL-C most proximal, but within 1 year before April 1, 2008, was deemed the qualifying LDL-C and used to determine LDL-C goal attainment. Lipid-lowering medication(s) for those attaining goal and factors associated with failure to attain LDL-C goal also were identified.
A total of 7427 patients were included in the study. A total of 3226 patients attained a LDL-C less than 70 mg/dL. The majority (92.4%) attaining goal were receiving statin monotherapy or in combination compared with 81.3% not at goal (P < .001). More than one-half attained goal on statin monotherapy with 70.7% at moderate- to high-potency doses and 87.4% on generically available statin. Nearly one-third attaining goal received statin in combination. Ezetimibe (70.6%) was most frequently used with statin. Factors independently associated with failure to attain a LDL-C less than 70 mg/dL were age younger than 65 years, patients not receiving statin, a history of creatine kinase elevation, and female sex.
This study reports the greatest rate of LDL-C less than 70 mg/dL goal attainment in a very high-risk population with CAD to date. However, despite a system dedicated to aggressively treat to a LDL-C goal of less than 70 mg/dL, success in the majority is a challenge with the currently available therapies.
国家胆固醇教育计划指南为冠心病(CAD)极高危患者提供了一个可选的低密度脂蛋白胆固醇(LDL-C)目标,即低于 70mg/dL。本研究评估了使用目前可用的降脂治疗达到这一建议的程度。
这是一项回顾性、横断面研究,纳入 Kaiser Permanente Colorado 医疗系统中年龄在 18 岁及以上的 CAD 患者,且 LDL-C 目标设定为低于 70mg/dL。最接近但在 2008 年 4 月 1 日之前 1 年内的 LDL-C 被视为合格 LDL-C,并用于确定 LDL-C 目标的实现情况。还确定了达到目标的降脂药物和未能达到 LDL-C 目标的相关因素。
共纳入 7427 例患者。共有 3226 例患者达到 LDL-C 低于 70mg/dL。大多数(92.4%)达到目标的患者接受了他汀类药物单药治疗或联合治疗,而未达到目标的患者为 81.3%(P<.001)。超过一半的患者在他汀类药物单药治疗下达到目标,其中 70.7%的患者使用中等至高强度剂量,87.4%的患者使用通用他汀类药物。近三分之一的患者接受了他汀类药物联合治疗。最常与他汀类药物联合使用的是依折麦布(70.6%)。未能达到 LDL-C 低于 70mg/dL 的独立相关因素包括年龄小于 65 岁、未接受他汀类药物治疗、肌酸激酶升高史和女性。
本研究报告了迄今为止 CAD 极高危人群 LDL-C 低于 70mg/dL 目标的最高达标率。然而,尽管有一个致力于将 LDL-C 目标降低到低于 70mg/dL 的系统,但在大多数情况下,目前可用的治疗方法仍然是一个挑战。